Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing (Contributions to Management Science)

by Gerrit Reepmeyer (Author)

• Used

  Paperback
  2005

  $31.61

  Monopoly profits have started to decline and the average costs per new drug have reached a re- cord level of close to US$ 1 billion today. As a result, any failure of a new sub- stance in the R&D process can lead to considerable losses, and the risks of introduc- ing a new drug to the market have grown tremendously.

• New

  Paperback
  2005

  $138.81

  Monopoly profits have started to decline and the average costs per new drug have reached a re- cord level of close to US$ 1 billion today. As a result, any failure of a new sub- stance in the R&D process can lead to considerable losses, and the risks of introduc- ing a new drug to the market have grown tremendously.